The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.
© National Comprehensive Cancer Network, Inc. 2011, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
Disclosures for the NCCN Guidelines Panel for Occult Primary
At the beginning of each NCCN Guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in JNCCN and online. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member.
Individual disclosures for the NCCN Guidelines for Occult Primary panel members can be found on page 1395. (The most recent version of these guidelines and accompanying disclosures, including levels of compensation, are available on the NCCN Web site at www.NCCN.org.)
These guidelines are also available on the Internet. For the latest update, visit www.NCCN.org.
Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT, Lawrence TS, Rosenburg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Vol. 2. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:2363-2387.
Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
Hainsworth JD, Lawrence M, Weiss LM. Carcinoma of an unknown primary site. In: Pazdur R, Wagman LD, Camphausen C, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach, 12th ed. Norwalk (CT): CMPMedica LLC; 2009.
Bugat R, Bataillard A, Lesimple T et al.. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003;89(Suppl 1):S59-66.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
Hemminki K, Ji J, Sundquist J, Shu X. Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol 2011;29:435-440.
van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003;14:191-196.
Briasoulis E, Tsokos M, Fountzilas G et al.. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 1998;18:1907-1914.
Stelow EB, French CA. Carcinomas of the upper aerodigestive tract with rearrangement of the nuclear protein of the testis (NUT) gene (NUT midline carcinomas). Adv Anat Pathol 2009;16:92-96.
French CA, Kutok JL, Faquin WC et al.. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004;22:4135-4139.
Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988;109:364-371.
Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
Hess KR, Abbruzzese MC, Lenzi R et al.. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999;5:3403-3410.
Abbruzzese JL, Abbruzzese MC, Hess KR et al.. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994;12:1272-1280.
van de Wouw AJ, Jansen RL, Griffioen AW, Hillen HF. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004;24:297-301.
Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol 2009;36:44-51.
Lenzi R, Hess KR, Abbruzzese MC et al.. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol 1997;15:2056-2066.
Jereczek-Fossa BA, Jassem J, Orecchia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev 2004;30:153-164.
Wick MR. Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors. Ann Diagn Pathol 2008;12:72-84.
Varadhachary GR, Greco FA. Overview of patient management and future directions in unknown primary carcinoma. Semin Oncol 2009;36:75-80.
Bahrami A, Truong LD, Ro JY. Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 2008;132:326-348.
Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-972.
Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-830.
Wick MR, Lillemoe TJ, Copland GT et al.. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 1989;20:281-287.
Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med 2010;134:216-224.
Talantov D, Baden J, Jatkoe T et al.. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn 2006;8:320-329.
Varadhachary GR, Talantov D, Raber MN et al.. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008;26:4442-4448.
Ma XJ, Patel R, Wang X et al.. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465-473.
Greco FA, Spigel DR, Yardley DA et al.. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010;15:500-506.
Hainsworth JD, Spigel DR, Rubin MS et al.. Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: a prospective, phase II trial [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 10540.
Greco FA, Lennington WJ, Spigel DR et al.. Carcinoma of unknown primary site (CUP): outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy [abstract]. J Clin Oncol 2011;29(Suppl 1):Abstract 3563.
Dumur CI, Lyons-Weiler M, Sciulli C et al.. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn 2008;10:67-77.
Monzon FA, Lyons-Weiler M, Buturovic LJ et al.. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009;27:2503-2508.
Monzon FA, Dumur CI. Diagnosis of uncertain primary tumors with the Pathwork tissue-of-origin test. Expert Rev Mol Diagn 2010;10:17-25.
Rosenwald S, Gilad S, Benjamin S et al.. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010;23:814-823.
Varadhachary GR, Spector Y, Abbruzzese JL et al.. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary (CUP). Clin Cancer Res 2011;17:4063-4070.
Woods RL, Fox RM, Tattersall MH et al.. Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. N Engl J Med 1980;303:87-89.
Goldberg RM, Smith FP, Ueno W et al.. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 1986;4:395-399.
Eagan RT, Therneau TM, Rubin J et al.. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 1987;10:82-85.
Milliken ST, Tattersall MH, Woods RL et al.. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987;23:1645-1648.
Alberts AS, Falkson G, Falkson HC, van der Merwe MP. Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. Med Pediatr Oncol 1989;17:188-192.
Becouarn Y, Brunet R, Barbe-Gaston C. Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. Eur J Cancer Clin Oncol 1989;25:861-865.
Schneider BJ, El-Rayes B, Muler JH et al.. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 2007;110:770-775.
Greco FA, Burris HA III, Litchy S et al.. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20:1651-1656.
Moller AKH, Pedersen KD, Gothelf A, Daugaard G. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol 2010;49:423-430.
Hainsworth JD, Erland JB, Kalman LA et al.. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997;15:2385-2393.
Greco FA, Gray J, Burris HA et al.. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 2001;7:203-212.
Hainsworth JD, Spigel DR, Farley C et al.. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-1752.
Hainsworth JD, Spigel DR, Thompson DS et al.. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 2009;14:1189-1197.
van der Gaast A, Verweij J, Henzen-Logmans SC et al.. Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol 1990;1:119-122.
Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992;10:912-922.
Briasoulis E, Kalofonos H, Bafaloukos D et al.. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000;18:3101-3107.
Hainsworth JD, Spigel DR, Clark BL et al.. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 2010;16:70-75.
- Search Google Scholar
- Export Citation
. Hainsworth JD Spigel DR Clark BL Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 2010; 16: 70- 75.
Huebner G, Link H, Kohne CH et al.. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 2009;100:44-49.
Greco FA, Rodriguez GI, Shaffer DW et al.. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004;9:644-652.
Greco FA, Erland JB, Morrissey LH et al.. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-215.
Pentheroudakis G, Briasoulis E, Kalofonos HP et al.. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol 2008;47:1148-1155.
Culine S, Lortholary A, Voigt JJ et al.. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study—trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003;21:3479-3482.
- Search Google Scholar
- Export Citation
. Culine S Lortholary A Voigt JJ Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study—trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21: 3479- 3482.
Pouessel D, Culine S, Becht C et al.. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004;100:1257-1261.
Jeremic B, Zivic DJ, Matovic M, Marinkovic J. Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. J Chemother 1993;5:262-265.
- Search Google Scholar
- Export Citation
. Jeremic B Zivic DJ Matovic M Marinkovic J Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. J Chemother 1993; 5: 262- 265.
Khansur T, Allred C, Little D, Anand V. Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. Cancer Invest 1995;13:263-266.
Hitt R, Lopez-Pousa A, Martinez-Trufero J et al.. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-8645.
- Search Google Scholar
- Export Citation
. Hitt R Lopez-Pousa A Martinez-Trufero J Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636- 8645.
Pointreau Y, Garaud P, Chapet S et al.. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498-506.
Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006;24:3548-3554.
Ekeblad S, Sundin A, Janson ET et al.. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991.
Kulke MH, Stuart K, Enzinger PC et al.. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406.
Okamoto H, Watanabe K, Kunikane H et al.. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162-169.
Fjällskog ML, Granberg DP, Welin SL et al.. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-1107.
Bucci MK, Bevan A, Roach M. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005;55:117-134.
Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol 2011;38:70-86.
Demir H, Berk F, Raderer M et al.. The role of nuclear medicine in the diagnosis of cancer of unknown origin. Q J Nucl Med Mol Imaging 2004;48:164-173.
Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003;44:1301-1314.
Kole AC, Nieweg OE, Pruim J et al.. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160-1166.
Seve P, Billotey C, Broussolle C et al.. The role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007;109:292-299.
Podoloff DA, Ball DW, Ben-Josef E et al.. NCCN Task Force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 2009;7(Suppl 2):1-26.
Gutzeit A, Antoch G, Kuhl H et al.. Unknown primary tumors: detection with dual-modality PET/CT—initial experience. Radiology 2005;234:227-234.
Hu M, Zhao W, Zhang PL et al.. Clinical applications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary. Chin Med J (Engl) 2011;124:1010-1014.
Nanni C, Rubello D, Castellucci P et al.. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 2005;32:589-592.
Pelosi E, Pennone M, Deandreis D et al.. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 2006;50:15-22.
Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 2009;19:731-744.
Ambrosini V, Nanni C, Rubello D et al.. 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med 2006;111:1146-1155.
Bhatia SK, Saclarides TJ, Witt TR et al.. Hormone receptor studies in axillary metastases from occult breast cancers. Cancer 1987;59:1170-1172.
Bleicher RJ, Morrow M. MRI and breast cancer: role in detection, diagnosis, and staging. Oncology (Williston Park) 2007;21:1521-1528.
Olson JA, Morris EA, Van Zee KJ et al.. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000;7:411-415.
Stomper PC, Waddell BE, Edge SB, Klippenstein DL. Breast MRI in the evaluation of patients with occult primary breast carcinoma. Breast J 1999;5:230-234.
Buchanan CL, Morris EA, Dorn PL et al.. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 2005;12:1045-1053.
Strnad CM, Grosh WW, Baxter J et al.. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 1989;111:213-217.
Guarischi A, Keane TJ, Elhakim T. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 1987;59:572-577.